secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004224
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos doubles TCR library addressable market; cash runway into Q4 2023
------------------------------------------------------------------------

- Added two new TCRs to library, doubling addressable market; targets KRAS, TP53, EGFR hotspot mutations.
- Enrolling patients in TCR-T Phase 1/2; third patient dosed Dec 2022; interim data expected mid-2023.
- Manufacturing capacity doubled; moving to cryopreserved product reduces process time 13% (30 to 26 days).
- mbIL-15 program IND filing anticipated H2 2023.
- Cash $39.1M (unaudited) plus $13.9M restricted; runway into Q4 2023; operating cash flow $35-40M in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523004224/0001193125-23-004224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523004224/d410539d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer